Just call it LLNS: LyonHeart roars no more

Share this article:
Just call it LLNS: LyonHeart roars no more
Just call it LLNS: LyonHeart roars no more
The agency formerly known as LyonHeart is going back to its maiden name ahead of the rollout of a new Omnicom healthcare agency network.

“We found that a lot of [client] companies were still calling us LLNS, including our biggest client,” said Sharon Callahan, who will serve as CEO of the new network, which is launching in October. “It seems like a lot of the equity is in LLNS, and we don't want to confuse the marketplace with another new name,” she added.
Callahan was mum on the details of the new network but said it will be an integrated offering consisting of five agencies, with PR, CRM, managed care consulting and med ed.

LLNS, also known as Lyons Lavey Nickel Swift, rebranded under the LyonHeart name in 2007, shortly after it was folded into the TBWA\WorldHealth network. LLNS was quietly demerged from TBWA earlier this year. The shop's top clients include Pfizer, Eisai, Daiichi Sankyo and Jazz Pharmaceuticals.

The new network, said Callahan, will be based on the recent global integration of a big pharma client's business across Omnicom, which she presided over. The process took two years.

“We found out what worked,” said Callahan. “We're trying to achieve true collaboration across disciplines.”

Callahan was EVP healthcare for Omnicom's Diversified Agency Services group before taking the CEO post at the new network. Anne Devereux, who was chairman and CEO of TBWA/WorldHealth, is chairman of the new network. Devereux is currently on medical leave.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...